DILAUDID Drug Patent Profile
✉ Email this page to a colleague
When do Dilaudid patents expire, and what generic alternatives are available?
Dilaudid is a drug marketed by Fresenius Kabi Usa and Rhodes Pharms and is included in three NDAs. There are two patents protecting this drug and two Paragraph IV challenges.
This drug has twenty-two patent family members in twelve countries.
The generic ingredient in DILAUDID is hydromorphone hydrochloride. There are fourteen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the hydromorphone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Dilaudid
A generic version of DILAUDID was approved as hydromorphone hydrochloride by HIKMA on July 29th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DILAUDID?
- What are the global sales for DILAUDID?
- What is Average Wholesale Price for DILAUDID?
Summary for DILAUDID
International Patents: | 22 |
US Patents: | 2 |
Applicants: | 2 |
NDAs: | 3 |
Finished Product Suppliers / Packagers: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 24 |
Clinical Trials: | 102 |
Patent Applications: | 5,157 |
Drug Prices: | Drug price information for DILAUDID |
Drug Sales Revenues: | Drug sales revenues for DILAUDID |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DILAUDID |
What excipients (inactive ingredients) are in DILAUDID? | DILAUDID excipients list |
DailyMed Link: | DILAUDID at DailyMed |
Recent Clinical Trials for DILAUDID
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 2 |
The Cleveland Clinic | N/A |
Hennepin Healthcare Research Institute | Phase 4 |
Pharmacology for DILAUDID
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |
Paragraph IV (Patent) Challenges for DILAUDID
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DILAUDID | Tablets | hydromorphone hydrochloride | 2 mg, 4 mg, and 8 mg | 019892 | 1 | 2013-08-05 |
DILAUDID | Oral Solution | hydromorphone hydrochloride | 5 mg/5mL | 019891 | 1 | 2011-02-25 |
US Patents and Regulatory Information for DILAUDID
DILAUDID is protected by two US patents.
Patents protecting DILAUDID
Packaging system for oxygen-sensitive drugs
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Drug container
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-006 | Jan 16, 2020 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Fresenius Kabi Usa | DILAUDID-HP | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-002 | Aug 4, 1994 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-004 | Apr 30, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-007 | Feb 10, 2017 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Rhodes Pharms | DILAUDID | hydromorphone hydrochloride | TABLET;ORAL | 019892-003 | Nov 9, 2007 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-004 | Apr 30, 2009 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DILAUDID
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Rhodes Pharms | DILAUDID | hydromorphone hydrochloride | SOLUTION;ORAL | 019891-001 | Dec 7, 1992 | ⤷ Sign Up | ⤷ Sign Up |
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-003 | Apr 30, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Rhodes Pharms | DILAUDID | hydromorphone hydrochloride | TABLET;ORAL | 019892-001 | Dec 7, 1992 | ⤷ Sign Up | ⤷ Sign Up |
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-004 | Apr 30, 2009 | ⤷ Sign Up | ⤷ Sign Up |
Rhodes Pharms | DILAUDID | hydromorphone hydrochloride | TABLET;ORAL | 019892-003 | Nov 9, 2007 | ⤷ Sign Up | ⤷ Sign Up |
Fresenius Kabi Usa | DILAUDID | hydromorphone hydrochloride | INJECTABLE;INJECTION | 019034-005 | Apr 30, 2009 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DILAUDID
See the table below for patents covering DILAUDID around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Japan | 2016512455 | 酸素感受性薬物用の包装システム | ⤷ Sign Up |
Spain | 2693123 | ⤷ Sign Up | |
European Patent Office | 2003134 | Compositions d'hydromorphinone (Hydromorphinone compositions) | ⤷ Sign Up |
Hungary | E041597 | ⤷ Sign Up | |
Denmark | 2968729 | ⤷ Sign Up | |
Germany | 60039711 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |